John Gever is a freelance writer who contributes to MedPage Today. His articles cover a wide range of topics in the medical field, including studies on various diseases, treatment options, and healthcare disparities. John's writing aims to provide accurate and informative insights into the latest developments in medicine and healthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Sham-controlled trial shows benefit in refractory disease with implantable device
— It might even help, researchers say Worries that urate-lowering therapy (ULT) could speed renal failure in patients with gout and chronic kidney disease (CKD) are unfounded, data from Great Britain indicated.
— Not so stomach-safe after all? Widespread belief holds that the popular over-the-counter painkiller acetaminophen does not cause stomach ulcers, but a new study from Great Britain puts that in doubt.
— Some educational materials require college-level reading ability Patient education materials (PEMs) in rheumatology and general medicine demanded greater literacy than is typically recommended, researchers found.
— Small trial suggests a simpler path to defeat systemic sclerosis
By: John
Fewer complications and flares occur for those who achieve the target, even intermittently
— Case-control study reinforces connection between inflammation and HFpEF
— Off-the-shelf drug reduces skin inflammation in animal models and human cell culture
— Leading adalimumab brand still dominates market, but net spending plummeted
— Hypothesized, but evidence not as clear until now Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors
(833) 317-6278 
